Literature DB >> 11398187

Histochemical study of acute and chronic intraperitoneal nicotine effects on several glycolytic and Krebs cycle dehydrogenase activities in the frontoparietal cortex and subcortical nuclei of the rat brain.

L Turégano1, R Martínez-Rodríguez, M I Alvarez, R R Gragera, A Gómez de Segura, E De Miguel, A Toledano.   

Abstract

The effects of nicotine on the activity of different dehydrogenases in frontoparietal regions and subcortical nuclei of the rat brain have been studied using histochemical methods. Nicotine sulphate was intraperitoneally administered in acute (4 mg/kg/day x 3 days) or chronic (ALZET osmotic pump providing 2 mg/kg/day x 15 days) doses. The enzymes analyzed were glyceraldehyde-3-phosphate, lactate, malate and succinate dehydrogenases (gly3PDH, LDH, MDH, and SDH, respectively). The results demonstrate that chronic as well as acute administration of nicotine produced strong increases in all these enzymatic activities in the superior layers (I, II and III) of the frontoparietal cortex (cingulate, motor and somatosensory regions); but high increases were not seen in the deeper layers of the cortex or in the subcortical nuclei (substantia nigra, caudate-putamen, nucleus accumbens or nucleus basalis magnocellularis). These hyperactivities were produced in brain regions with normally low enzymatic activity (cortex), but not in those with great intensity (subcortical nuclei). The results are in rough agreement with previous reports on nicotine-induced increases in glucose utilization, gly3PDH genic expression and neuronal hyperactivity in the brain cortex; but significant discrepancies between the cortical enzymatic maps and those obtained both in these studies and others on nicotine(N)-receptor localization have been appreciated. The results support the hypothesis that nicotinic cholinergic drugs can have metabolic, long-lasting stimulant effects on cortical neurons at specific points (probably layer III pyramidal cells and structures with alpha7-N-receptors) of the cortical circuits that could be of great interest in improving altered cognitive functions that are present in Alzheimer disease, as well as in other less severe mental disturbances. Mitochondrial hyperfunction should also be evaluated as a possible side-effect (as an oxidative stress inductor) of these kinds of drugs. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398187     DOI: 10.1002/jnr.1116

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  5 in total

1.  Exercise Rehabilitation and/or Astragaloside Attenuate Amyloid-beta Pathology by Reversing BDNF/TrkB Signaling Deficits and Mitochondrial Dysfunction.

Authors:  Yu-Lin Wang; Chung-Ching Chio; Shu-Chun Kuo; Chao-Hung Yeh; Jui-Ti Ma; Wen-Pin Liu; Mao-Tsun Lin; Kao-Chang Lin; Ching-Ping Chang
Journal:  Mol Neurobiol       Date:  2022-03-09       Impact factor: 5.590

2.  Immunohistochemical increase in cyclooxygenase-2 without apoptosis in different brain areas of subchronic nicotine- and D-amphetamine-treated rats.

Authors:  A Toledano; M I Alvarez; I Caballero; P Carmona; E De Miguel
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

3.  Significant modulation of mitochondrial electron transport system by nicotine in various rat brain regions.

Authors:  Ju Wang; Jong-Man Kim; David M Donovan; Kevin G Becker; Ming D Li
Journal:  Mitochondrion       Date:  2009-01-30       Impact factor: 4.160

Review 4.  Mitochondria as a possible target for nicotine action.

Authors:  Dominika Malińska; Mariusz R Więckowski; Bernadeta Michalska; Karolina Drabik; Monika Prill; Paulina Patalas-Krawczyk; Jarosław Walczak; Jędrzej Szymański; Carole Mathis; Marco Van der Toorn; Karsta Luettich; Julia Hoeng; Manuel C Peitsch; Jerzy Duszyński; Joanna Szczepanowska
Journal:  J Bioenerg Biomembr       Date:  2019-06-13       Impact factor: 2.945

5.  Glutamatergic and GABAergic metabolism in mouse brain under chronic nicotine exposure: implications for addiction.

Authors:  Mohammad Shameem; Anant Bahadur Patel
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.